Brief: Synlogic Achieves Research Milestone In Collaboration With Roche For Development Of Novel Synthetic Biotic To Treat Inflammatory Bowel Disease
06/09/2022 12:40
Sept 6 (Reuters) - Synlogic Inc SYBX.O :
* SYNLOGIC ACHIEVES RESEARCH MILESTONE IN COLLABORATION WITH
ROCHE
FOR DEVELOPMENT OF NOVEL SYNTHETIC BIOTIC TO TREAT INFLAMMATORY
BOWEL DISEASE
Source text for Eikon: ID:nGNX498ng0
Further company coverage: SYBX.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Synlogic
See all newsBrief: Synlogic Receives Letter From Nasdaq Listing Qualifications Department On Nov 21 - SEC Filing
Brief: Synlogic Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Synlogic Inc reports results for the quarter ended September 30 - Earnings Summary
Synlogic Inc expected to post a loss of 10 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in January - Earnings Summary